The use of AHF in the rat as a predictive lesion for carcinogenesis has been frequently suggested. Regulatory agencies require that the data used to determine carcinogenic potential and for estimating risk cannot be open to different interpretations. The degree of uncertainty in establishing relationships between the different foci phenotypes, their fate, and the difference in results with different protocols precludes the use of these data is establishing carcinogenic hazard or in quantitative risk estimation.
The mandate of the Health Protection Branch, Department of National Health and Welfare Canada is to provide a regulatory framework, and enforcement of regulations, designed to ensure the safety of materials, specifically food, drugs and medical devices made available to the Canadian public. Within this mandate, the Branch directly administers the Food and Drugs Act and functions in an advisory capacity to Departments administering several other Acts including the Pest Control Products Act (Pesticides), Water Quality Act, and the Canadian Environmental Protection Act.
The Branch is composed of 6 Directorates: Food Directorate, Drugs Directorate, Environmental Health Directorate, Laboratory Centre for Disease Control, Field Operations Directorate, and the Federal Centre for AIDS. The Food Directorate responsibility includes the assessment of safety of materials added to or used in food, food processing or food packaging, including food additives, pesticides, contaminants and processing chemicals. Much of the emphasis of the Directorate is placed on the assessment Of potential hazard and/or associated risk from exposure to chemicals, including assessment of potential carcinogenicity of chemicals. Im-plicit in this assessment is the qualifier "human or potential human carcinogen.** There is no direct unequivocal translation from rodent to human in terms of carcinogenic potential, and the additional caveat that "the dose makes the poison," is significant. It should be noted that evidence of animavrodent tumorigenicity or carcinogenicity is not of itself sufficient to require the application of the more stringent procedures for risk assessment and risk management associated with the designation potential human carcinogen.
In making these assessments, the Health Protection Branch utilizes the "weight of evidence** paradigm in assigning the designation "carcinogen" to a chemicallmaterial, especially in assessing the probability effect on the human population. What is weight of evidence? Evidence of human carcinogenicity from adequate epidemiological or direct human exposure data outweighs all other data and results in a positive designation. All other evidence, more specifically the data from animal (rodent) bioassay studies and such supporting studies as metabolism, toxicokinetics, reproduction, genotoxicity and chronic studies are assessed in an iterative manner. With increasing frequency the use of mechanistic models to explain assay results are also included in the assessment. The presence of an increased incidence of tumors in the rodent bioassay study, their type and location, would be considered in the light of the dose regimen, dose response, metabolic overload and Positive or negative genotoxicity data. These data are incorporated into a bio-
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Toxloo~o~~c PATHOLOOY logical risk assessment using weight of evidence (1). The Food Directorate uses an approach to the classification of the pathology of lesions similar to that of the NTP (3), in that there are at least 4 designated hepatocellular lesions: foci of cellular alteration, hyperplasia, adenoma, and carcinoma. Only 2 of these lesions would be considered to be neoplastic, adenomas, and carcinomas. Recent consensus has indicated that the term "neoplastic nodule" is not an appropriate description of the hyperplastic stage of rat liver foci (3). The Branch position is that benign lesions indicate potential tumorigenicity, whereas malignant lesions indicate potential carcinogenicity. Where do "altered hepatic foci" (AHF) fit into this scheme? Three questions are posed: does the Food Directorate requestlreceive data on altered hepatic foci in the rat as part of the registration data requirements for chemicals; does the Directorate utilize these data in assessing "carcinogenicity," and if so how; and finally, what additional information would the Directorate require to use the altered hepatic foci data in assessing carcinogenicity?
In the data requests for rodent bioassays, or indeed any study with a pathology component, the Directorate requires that all observed lesions including altered hepatic foci are reported. This is an integral part of the database, and it is assumed that the absence of data on altered foci indicate that no foci were detected. Altered foci are usually identified by hematoxylin and eosin (H&E) stain and may be categorized as clear, basophilic, acidophilic, or mixed. Since the gradation of classification from altered hepatic foci to hyperplastic nodule to adenoma through to carcinoma is dependent on the interpretation of the study pathologist, the Directorate also requests a detailed written definition of the identification criteria for each lesion, and in addition photomicrographs whenever possible. The use of electron micrographs would, in some cases, also be very helpful in defining the physiological state of the cells. It is a rarity for the reports to contain information on the foci other than the tinctorial properties or morphological descriptors. Such additional information as the enzymatic phenotype, e.g., gamma glutamyl transferase positive, glucose-6-phosphatase negative are rarely included.
What is known about AHF in rats? AHF are found in untreated rats of both sexes, and increase in both number and size with age (10, 20, 22) . The range of incidence in control animals is greatly dependent on the methodology of examination and on the strain (1 6). The elegant work of Harada et a1 (1 2) indicates that for the Fischer 344 rat, the incidence may be 100% in control animals by 2 yr, and approaches 100% by 15 months. These foci are identified by H&E strain. Stereometric analysis of the foci indi-cate that the incidence and size increase with age. The incidence is sex related with increased basophilic foci in females and increased clear foci in males.
Farberand others have expressed the opinion that AHF are indicative of preneoplasia and can be used as an index of carcinogenicity (21, 27, 28). It is important to note that there are several different identifiable types of altered foci dependent on both cytochemical and histochemical methods used to examine foci. Many of these foci will regress following cessation of exposure to the inducing chemical, and therefore do not fulfill one of the necessary cnteria for carcinogenicity, i.e.. irreversibility (7,9,24, 3 1). If the initiation, promotion, progression model of carcinogenesis is accepted, the proposition posed is that cells in the AHF represent initiated cells. These cells need a second stimulus to progress to committed transformed cells. Most authorities agree that altered foci in rodent livers are indicative of a modified physiological state, and that in the rat many AHF are more reflective of an adaptation rather than a true neoplastic lesion (8. 19 ).
Some of the difficulties in using AHF foci in a regulatory framework can be summarized as follows: 1) Hyperplasiu: There is evidence that the cell growth seen in altered foci is not the same qualitatively as that seen in tumors. Is cell division and growth as exemplified by the Partial Hepatectomy/ Initiator (PH) model or the NecrosidInitiator (NI) model the same as the non-regenerative hyperplasia seen in mitogen treatment, as for instance in animals treated with peroxisomal proliferative agents? If the underlying mechanism of stimulation of cell growth in these lesions is not the same, then are the foci the same, and should they be treated the same? Some evidence would indicate that the events are not similar (l8), and that the fate of some cells in these hyperplastic areas are not identical. There is increased "apoptosis" (programmed cell death) following the mitogenic wave in the non-reparative cell division.
2) Enzyrnafic character: Several different enzymatichistochemicallphysiological characters have been used in different studies that identify altered foci: namely, glutathione-S-transferase P (placental type) positive (GSTP +ve); gamma-glutamyl transferase positive (GGT +ve); ATPase deficient (AT-Pase -ve); glucose-6-phosphate dehydrogenase positive (G-6-PD +ve); glucose-6-phosphatase deficient (G-6-P -ve); glycogen storage (GLY +ve); iron excluding (FE -ve); mixed function oxidase deficient; and amphophilic (non-homogenously distributed basophilic material). Zerban et a1 (33) histochemical marker for hepatic foci. There is evidence that the enzymatic state and/or physiological state of foci induced by "non-genotoxic" chemicals such as peroxisomal proliferative chemicals is not the same as foci induced by "genotoxic chemicals." There are also indications that foci in control animals differ histochemically or in physiology from those found in animals treated with classical "genotoxic carcinogens" (2, 14, 16, 32) .
3) Physiology: The cells of altered hepatic foci have been identified as differing in ploidy level, mitotic index, ability to form DNA adducts with known adduct forming chemicals, loss of intercellular communication and, in a progressive manner, in altered morphology from the surrounding parenchyma. Many of these changes in physiology are both important and to be expccted on theoretical grounds depending on the paradigm of choice for the carcinogenic mechanism. Most interpretations are based on the multistage model. Within the context of this model, there are several critical inconsistencies, specifically, the anachronism of differences between the inducing effects of regenerative hyperplasia and the non-regenerative hyperplasia of mitotic agents, e.g., peroxisomal proliferative agents, lead citrate, ethylene dibromide (2, 18, 32) . If there are significant differences in the underlying mechanisms of fixation for initiated cells, or of the susceptibility of initiated celldfoci to "apoptosis" (programmed cell death) that depend on the protocol for inducing the effect, then how relevant is the effect as a regulatory system index? 4) Fare: The fate of the altered foci is a Critical question in terms of assessing their relevance to carcinogenesis. Regression is a well-documented characterisitc of many AHF following cessation of exposure to the inducing chemical. However, it is not certain if all foci type regress at the same rate, if all types are capable of progression to frank neoplasia, if the residuavpersistent foci are all derived from the same type, and if the resurgent foci at later time periods are derived from all foci types or only one. Additionally, there is evidence that there may be a continuous progression through the foci types to the final pre-neoplastic lesion (5, 17, 30) , which sheds a different complexion on the "clonal origin" of foci and the concomitant assumption of initiated cells. Data on "apoptosis" is beginning to emerge as a germane issue in the fate of AHF.
In studies on Sprague Dawley rat liver, Enzmann and Bannasch (5) have indicated that there is a sequential progression through the various types of foci, as indicated by their histochemistry, e.g., clear (glycogen storage), to mixed cell foci to basophilic cell foci. They suggest that the transition is not a consequence of monoclonal expansion within the foci, but a real alteration or metamorphosis of large cell populations from one type to the other as the foci expand and age. Tatematsu et a1 (29) also discuss the transition from one phenotype to another within AHF. They describe foci within foci and nodules within nodules, coupled with an increase in size of the non-regressing foci. The nodules within nodules are of a further advanced histochemically identified cell type. The cells of these nodules within nodules usually exhibit advanced morphological changes relative to normal parenchyma. These authors use a modified Solt-Farber protocol with PH and treatment with either acetyl aminofluorene (AAF), phenobarbital (PB) or butylated hydroxyanisole (BHA) following initiation with diethylnitrosamine (DEN). They suggest that the fate of AHF may be summarized as follows: 1) normal hepatocytcs are "initiated" with a carcinogen and develop into AHF; 2) a few AHF develop into neoplastic nodules, and if stimulated strongly enough with AAF and PH, some may form hyperplastic altered foci with compression of surrounding parenchyma; 3) what the exact difference is between hyperplastic AHF and neoplastic nodules is not indicated; and 4) if the stimulus is removed and the altered phenotype reverts but the nodule remains, these were hyperplastic nodules and it is in this group that progression to nodules within nodules occurs.
Harada et a1 (13) examined tissue from several carcinogenicity bioassays and draw the conclusion that there is a potential for prediction of carcinogenicity based on the incidence of AHF identified by H&E stain. They identified what are termed "atypical" basophilic and eosinophilic foci. The incidence of these atypical foci increased in a doseand treatment-related manner. The foci were chemical specific, and at least for the atypical eosinophilic foci, these may represent the amphophilic foci of Weber et al (30) .
The critical question to be addressed at this time is, at what point can the information developed and presented by basic research be integrated into a regulatory framework? Is the hypothesis presented m-cia1 to the regulatory function and does it add significantly to the reliability, scope or precision of the regulatory function? These questions are, in part, determined by the paradigm used in the regulatory framework, and in part, by the degree of agreement and support the hypothesis achieved within the scientific community.
What of AHF? As indicated above, there is some evidence that AHF, or a subset of AHF are a preneoplastic lesion. Some of these lesions, or subsets thereof, or latent modifications within them, are thought to give rise to neoplastic states; however, many or most of these lesions regress. Questions arise concerning the significance of foci phenotype, the relationship between long-lived foci, regressed foci and the late reappearance of neoplasia. What is the relationship between foci and benign tumors, and between benign and malignant tumors? (See Fig.   1 
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These models of multistage carcinogenesis are based on the 2 event hypothesis of Scherer and Emmelot (4, 26) as also proposed by Potter (23) . This demands a second rare event such as a mutation in any of the initiated cells. It is clear from several studies (6, 25) that initiated or modified cells are less stable than the surrounding parenchyma, but this does not fit well with the documented resistance of AHF cells to form DNA-adducts with known carcinogens. Thus, the AHF possess the same refractive character as the later stages of hepatic carcinogenesis (1 5). Information on the mechanism of carcinogenesis is critically important in understanding the why of the rodent bioassay results, and eventually determining the level of exposure, if any, that is equivalent to "safe." In the absence of a clear understanding of the events, including the number of events necessary for the development of a malignant state, or even benign tumors, the toxicologist is left with only the end product, presence or absence of tumors and peripheral information on which to base a decision. Since this decision has both social and economic impact, it is important that the rationale and the process be both understandable and defensible.
Would the use of"AHF" as evidence of "carcinogenicity" improve the regulatory requirement of assessment of safety by improving either the assessment of hazard or the assessment of risk? In the Directorate approach to the assessment of "carcinogenicity,** there is a separation between benign tumors (tumorigenicity) and malignant tumors (carcinogenicity) for assessing hazard. In the estimation of a permitted level of exposure, either a No Ob-servable Adverse Effect Level (NOAEL) and safety factor approach is used or the estimation of a Virtually Safe Dose (VSD) by quantitative risk estimation. How would data on AHF be used in regulatory toxicology and the assessment of carcinogenicity? The purpose of the assessment is as follows: 1) Determine if there is evidence of human carcinogenicity. Ifany data on human exposure are available. 2) Establish if there is evidence of animal carcinogenicity or tumorigenicity, using a weight of evidence approach. 3) In the event of positive animal studies, estimate the likelihood (relationship) of human effects at the dose levels indicated, using weight of evidence and biological risk assessment. 4) Where applicable establish a dose/ response relationship on probable human exposure (estimate of a VSD). And 5) Recommend appropriate action to the senior management.
The event of human carcinogenicity has already been dealt with. The discusison here concerns rodent, and specifically rat, data. Three scenarios cover the spectrum of possible submissions with increased incidences of AHF: 1) increased incidence of AHF alone; 2) increased incidences of AHF and benign tumors (adenoma); and 3) increased incidences of AHF, benign tumors and malignant tumors.
The endpoint used in assessing tumorigenicity and carcinogenicity is an increased evidence of tumors, either by type (rare), location or of common organ specific tumors in a rodent bioassay. If in the studies there is no increased incidence of tumors, then even with increased incidences of AHF, the material would not be considered tumorigenic/carcinogenic. Increased incidences of benign or malignant tumors provide sufficient data to establish their own endpoints. Since increased incidences of benign tumors do not initiate a mathematical risk estimate, the additional data on AHF would serve to provide a NOEL, but would not enhance the characterization of a chemical as a tumorigen. Increased incidences of AHF would add weight to the potential designation of a chemical as a tumorigen.
What are the requirements for using rat AHF as evidence of neoplasia? The equivalence of the different "foci types" must be established or the relevance of each type to the process of hepatocarcinogenesis. This has been approached, in part, by the work of Zerban et a1 (33, 34) . Their results indicate that, at least for N-nitrosoethanolamine, there is a singular correlation in the dose : time relationship between the appearance of "tumors" (type not specified) and the time to achieve an area density of 1% G6PDH or GGT positive foci. Other foci do not fall into these characteristic foci types but are apparent for H&E staining, e.g., amphophilic foci (30).
Further expansion of the work by Hannigan and
Pitot on the transplantation of foci cells into host animals is needed to establish progression to neoplasia (1 1). However, the additional treatment with the initiating agent, AAF, in this protocol renders this experimental protocol of dubious value to the regulator since it is not possible to ensure that treatment with the initiator did not influence the outcome for transplanted foci cells. The characteristics of "regression" and "resurgence of initiated" cells must be determined. If the initiated cells in a regressing foci do not actually disappear, what triggers their reappearance? Are the resurgent foci derived from cells that were thought to have regressed or remodeled, or are they from remnants of regressed foci? Are these secondary foci always from the same foci type, or from any of the original foci types? (See Fig. 2.) In conclusion, therefore, to answer the three questions posed: 1) Does Health and Welfare Canada request and get data on AHF in submissions for regulatory purposes? The answer to both parts is "yes." Generally, the data is in the form of H&E staining characteristics and morphology. 2) 1s the data usedhseful in assessing "carcinogenicity" in the regulatory sense? The answer is a qualified "no." It is of significant use in estimating tumorigenic POtential with data on increasing incidence and estab-lishment of a dose relationship considered to be supporting evidence of tumorigenic potential. Under the paradigm currently in use, it is not relevant to the assessment of carcinogenicity (malignant tumors). AHF are considered to have some preneoplastic character. In the absence of clear evidence of progression based on precise criteria for identification, these lesions are not assessed as evidence of neoplasia, nor subjected to risk methodology, with either human benign or malignant tumors. At this time, quantitative risk assessments would not be conducted on AHF data. 3) What would be required to further expand the use of AHF data in the hazard assessment/risk estimate process? Further work has to be done to clearly characterize the relationship between the different foci types. Fate studies on type and number of foci and evidence of progression must be available. The relationship between foci developing in control animals, chronic treatment nonmodeled studies, and those in model studies using the Peraino and Solt-Farber protocols should be determined. Data on specific foci types (histochemical analyses and morphometric analyses) would probably be required throughout the study period to permit a clear evaluation of hazard and risk (stop experiments).
At this time, the conflicting evidence with regards to foci type, physiology, fate and relationship to tumors, either benign or malignant, does not recommend the use of foci data in quantitative risk estimation, nor in the assessment of carcinogenic potential, but does permit their use in a weight of evidence assessment of hazard or biological risk assessment for tumorigenicity.
